Osteopenia. Menopausal and other perimenopausal disorders
Conditions
Interventions
Intervention 1: Intervention group: Treatment with 70 mg weekly Alendronate for 2 years. Intervention 2: Intervention group: Treatment with 35 mg weekly Alendronate for 2 years.
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to No maximum
Inclusion criteria
Inclusion criteria: Menopausal state Osteopenia (hip or spine T-score -2.5 to -1) Normal serum levels of vitamin D, Calcium, Phosphorus, Alkaline phosphatase Lacking history of pathological or traumatic fractures Lacking the diagnosis of malignancy
Exclusion criteria
Exclusion criteria: The impossibility to determine FRAX index due to any reason Osteoprosis (T-score worse than -2.5) Osteopenia (hip or spine T-score -2.5 to -1) plus pathological fracture
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hip FRAX. Timepoint: Immediately before intervention and within 2 years following intervention. Method of measurement: Bone mineral densitometry.;Spine FRAX. Timepoint: Immediately before intervention and within 2 years following intervention. Method of measurement: Bone mineral densitometry.;Hip T-score. Timepoint: Immediately before intervention and within 2 years following intervention. Method of measurement: Bone mineral densitometry.;Spine T-score. Timepoint: Immediately before intervention and within 2 years following intervention. Method of measurement: Bone mineral densitometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hip Z-score. Timepoint: Immediately before intervention and within 2 years following intervention. Method of measurement: Bone mineral densitometry.;Spine Z-score. Timepoint: Immediately before intervention and within 2 years following intervention. Method of measurement: Bone mineral densitometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMansour Karimifar
Esfahan University of Medical Sciences
Outcome results
None listed